Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 09, 2018 16:01 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
August 02, 2018 08:00 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on Thursday, August 9

SANTA MONICA, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions...
June 25, 2018 16:05 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Announces Receipt of First Tranche from National Institutes of Health Grant for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

Initial $500,000 to be Utilized to Advance the Development of OPNT003 SANTA MONICA, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty...
June 12, 2018 08:00 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors

SANTA MONICA, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
June 04, 2018 16:05 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals to Participate in Opioid Panel at the BIO International Convention

SANTA MONICA, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
May 29, 2018 08:00 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals to Participate in The American Society of Clinical Psychopharmacology 2018 Annual Meeting

Company’s Chief Scientific Officer, Phil Skolnick, Ph.D., to Receive ASCP’s “Donald Klein Lifetime Achievement Award” SANTA MONICA, Calif., May 29, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals,...
May 08, 2018 16:05 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions,...
May 03, 2018 08:00 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals To Host Key Opinion Leader Meeting on Medications for Addictions and Related Disorders

Key Opinion Leader Luncheon to Take Place in New York City on May 10 SANTA MONICA, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty...
April 18, 2018 08:00 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

Grant Expected to Fund Development of OPNT003 to NDA Ready Stage SANTA MONICA, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty...
March 19, 2018 16:05 ET | Source: Opiant Pharmaceuticals, Inc.

Opiant Pharmaceuticals, Inc. to Present a Corporate Overview at the Oppenheimer 28th Annual Healthcare Conference

SANTA MONICA, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...